Intravenous Infusions Plc

GHSE:IIL Stock Report

Market Cap: GH₵13.7m

Intravenous Infusions Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Moukhtar Soalihu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure4.3yrs
CEO ownershipn/a
Management average tenure3.6yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

CEO

Moukhtar Soalihu (53 yo)

4.3yrs

Tenure

Mr. Moukhtar M. Soalihu serves as Managing Director at Intravenous Infusions Plc since September 2020 and serves as its Executive Director. He served as Acting Managing Director of Intravenous Infusions Pl...

Leadership Team

NamePositionTenureCompensationOwnership
Moukhtar Soalihu
MD & Executive Director4.3yrsno datano data
Eugenia Bulley
General Manager of Finance & Administration3.6yrsno datano data
Kenneth Awude
General Manager of Technical & Operations3.6yrsno datano data
Isaac Nsiah-Afriyie
General Manager of Marketingless than a yearno datano data
Solomon Puplampu
Head Of Engineeringno datano datano data
Samuel Marfo
Head of Internal Auditno datano datano data

3.6yrs

Average Tenure

53yo

Average Age

Experienced Management: IIL's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Moukhtar Soalihu
MD & Executive Director4.3yrsno datano data
Isaac Osei
Non-Executive Chairman26.1yrsno datano data
Leon Appenteng
Non-Executive Director36.1yrsno datano data
Samuel Kwadjo Appenteng
Non-Executive Director36.1yrsno datano data
Gladys Amponsah
Independent Non-Executive Director10.5yrsno datano data
Williams Atulik
Independent Non-Executive Director5.7yrsno datano data
Emmanuel Blankson
Non-Executive Director4.9yrsno datano data
Nana Kwame Kyeretwie
Non-Executive Director1.5yrsno datano data

8.1yrs

Average Tenure

62yo

Average Age

Experienced Board: IIL's board of directors are considered experienced (8.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 22:31
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Intravenous Infusions Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution